ASH 2024 – J&J aims at a myeloma precursor
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
BeiGene tries where others failed
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hopes to be as efficacious as ex vivo therapy, with convenience and safety advantages.
